Table 1

Pneumococcal conjugate vaccines in recent randomised controlled phase II and phase III immunogenicity studies

Study vaccine Saccharides Protein carrier(s) Manufacturer Published studies Number immunised with study vaccine
7vCRM (Prevnar)2 μg of types 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of 6B CRM197 Wyeth LederleRennels et al, 199832 106
Shinefield et al, 199933 183
Black et al, 200034 18 927 (efficacy trial)
Chooet al, 200035 248
9vCRMAbove and 2 μg of types 1 and 5CRM197 Wyeth LederleMbelleet al, 199936 250
Obaroet al, 200037 103
11vTD1 μg of types 1, 4, 5, 7F, 9V, 19F, and 23F;Tetanus toxoidAventis PasteurPhase II trials in progress
3 μg of types 3, 14, and 18C, and 10 μg of 6B Diphtheria toxoid
11vOMP5–10 μg of types 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F Non-typable H influenzae outer membrane protein SmithKline BeechamPhase II trials starting